Nurix therapeutics reports case study of patient with aggressive non-hodgkin's lymphoma (nhl) showing a complete clinical response to nx-2127 at the 5th annual targeted protein degradation (tpd) summit

Complete response observed and ongoing in a patient with multiply relapsed/refractory diffuse large b cell lymphoma (dlbcl)

NRIX Ratings Summary

NRIX Quant Ranking